2023
Patterns of Care and Outcomes of Ambulatory Endovascular Interventions in Lower Extremity Peripheral Arterial Disease
Chaturvedi A, Castro-Dominguez Y, Gertz Z, Lawson B, Chandrika P, Gupta R, Milioglou I, Sung J, Desai N, Vetrovec G, Kochar A, Guha A. Patterns of Care and Outcomes of Ambulatory Endovascular Interventions in Lower Extremity Peripheral Arterial Disease. The American Journal Of Cardiology 2023, 194: 17-26. PMID: 36924641, DOI: 10.1016/j.amjcard.2023.02.006.Peer-Reviewed Original ResearchConceptsPatterns of careEndovascular interventionCardiovascular eventsLower Extremity Peripheral Arterial DiseaseLower extremity endovascular interventionsChronic kidney diseasePeripheral arterial diseasePeripheral artery diseasePrimary treatment modalityIschemic heart diseaseNon-Medicare insuranceUrban teaching facilityDisease refractoryUncontrolled hypertensionMost patientsArtery diseaseHeart failureArterial diseaseStudy cohortKidney diseaseMean ageNoninvasive managementTreatment modalitiesHeart diseaseFemale gender
2020
Outpatient Cost-effectiveness Study of Hyperkalemia Management
Desai N, Rowan C, Alvarez P, Fogli J, Coca S. Outpatient Cost-effectiveness Study of Hyperkalemia Management. Journal Of Cardiac Failure 2020, 26: s115. DOI: 10.1016/j.cardfail.2020.09.332.Peer-Reviewed Original ResearchOutpatient costsOptum's de-identified ClinformaticsEnd-stage renal diseaseMatched-cohort designData Mart DatabaseTreatment of hyperkalemiaMedicare Advantage populationCost-effectiveness studiesReal-world evidenceMEq/LCongestive HFHK cohortHyperkalemia managementPotassium bindersIndex dateCohort studyRenal diseaseOutpatient outcomesMean ageBaseline variablesInclusion criteriaPatiromerLarge cohortStudy populationCensoring event
2019
Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
Desai N, Rowan C, Alvarez P, Fogli J, Toto R. Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients. Journal Of Drug Assessment 2019, 8: 2-2. PMCID: PMC6764378, DOI: 10.1080/21556660.2019.1658287.Peer-Reviewed Original ResearchContinuous exposureRenin angiotensin aldosterone system inhibitor therapyAldosterone system inhibitor therapyDevelopment of hyperkalemiaCornerstone of therapyRetrospective cohort studyOptum Clinformatics DataMartMEq/LNational Health InsuranceBinder therapyHK cohortHyperkalemia treatmentPotassium bindersRAASi therapyIndex dateCohort studyInhibitor therapyContinuation ratesMean ageDiagnosis codesITT groupCardiovascular diseaseClinformatics DataMartMedicare patientsPatiromerThe Characteristics of Out-Patient Use of Intravenous Milrinone in the United States
Gottlieb S, Grabowsky T, Allen L, Kandel B, Apte J, Desai N, Ahmad T, Clark S, Psotka M, Lindefeld J, Francis G. The Characteristics of Out-Patient Use of Intravenous Milrinone in the United States. Journal Of Cardiac Failure 2019, 25: s88-s89. DOI: 10.1016/j.cardfail.2019.07.253.Peer-Reviewed Original ResearchMilrinone useAdvanced heart failure treatmentConcomitant medication useUse of milrinoneHeart failure treatmentBeta-adrenergic blockersOut-patient useNature of patientsTotal US populationFentanyl prescriptionsInotrope useIntravenous milrinoneCardiac medicationsLoop diureticsMedication useMean ageAcute eventOutpatient settingFailure treatmentAdrenergic blockersLife careMilrinoneLower prescriptionUS populationNational projections